Archive Newsletter

  1. 06.06.25 -- Inside The Trials Aiming To Stop Vision Loss For Rare Eye Disease Patients 6/6/2025
    06/06/25 Cell & Gene Newsletter
  2. 06.05.25 -- Extracellular Vesicle Production Requires Robust, Scalable, And Cost-Effective Processes In Order To Reach Full Potential 6/5/2025

    06/05/25 Cell & Gene Newsletter

  3. 06.05.25 -- Why Better Manufacturing Is The Key To Unlocking Cell Therapy's Full Potential 6/5/2025
    06/05/25 Cell & Gene Newsletter
  4. 06.04.25 -- Master The Final Critical Step In Drug Manufacturing 6/4/2025

    06/04/25 Cell & Gene Newsletter

  5. 06.04.25 -- First AMT Program OK'd Under New FDA Designation — Here's What To Know 6/4/2025
    06/04/25 Cell & Gene Newsletter
  6. 06.03.25 -- STREAM Edition: Harnessing AI And Synthetic Biology For Cell Therapies 6/3/2025
    06/03/25 Cell & Gene Newsletter
  7. 06.03.25 -- Will Genome Modifications Define Next-Gen AAV Vectors? 6/3/2025
    06/03/25 Cell & Gene Newsletter
  8. 06.02.25 -- Changes To The Global Clinical Trial Landscape 6/2/2025

    06/02/25 Cell & Gene Newsletter

  9. 06.02.25 -- Cell & Gene Therapy Manufacturing: Considerations For Early-Stage Companies 6/2/2025
    06/02/25 Cell & Gene Newsletter
  10. 05.30.25 -- Unlocking The Potential Of iPSC Therapies In Regenerative Medicine 5/30/2025
    05/30/25 Cell & Gene Newsletter